Associated Genetic Biomarkers
Hepatocyte growth factor (HGF) is a gene that encodes a protein that is involved in cell growth, motility, and morphogenesis. The protein, also known as hepatocyte growth factor, functions through the activation of a tyrosine kinase signaling pathway. Missense mutations, nonsense mutations, silent mutations, and frameshift insertions are observed in cancers such as lung cancer, parathyroid cancer, and skin cancer.
HGF is altered in 2.20% of all cancers with lung adenocarcinoma, cutaneous melanoma, colon adenocarcinoma, breast invasive ductal carcinoma, and conventional glioblastoma multiforme having the greatest prevalence of alterations .
The most common alterations in HGF are HGF Mutation (1.87%), HGF Amplification (0.26%), HGF E199K (0.04%), HGF Loss (0.04%), and HGF R220Q (0.02%) .
HGF status serves as an inclusion eligibility criteria in 3 clinical trials, of which 2 are open and 1 is closed. Of the trials that contain HGF status as an inclusion criterion, 2 are phase 1 (1 open) and 1 is no phase specified (1 open).
Trials with HGF status in the inclusion eligibility criteria most commonly target bladder carcinoma, breast carcinoma, colorectal carcinoma, diffuse intrinsic pontine glioma, and glioma .
The most frequent alteration to serve as an inclusion eligibility criterion is HGF Amplification .
Extended release flucytosine, savolitinib, and vocimagene amiretrorepvec are the most frequent therapies in trials with HGF as an inclusion criteria .
Significance of HGF in Diseases
Non-Small Cell Lung Carcinoma +
HGF is altered in 4.52% of non-small cell lung carcinoma patients .
HGF is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains HGF status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) .
Squamous Cell Lung Carcinoma +
HGF is altered in 3.19% of squamous cell lung carcinoma patients .
HGF is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HGF status and squamous cell lung carcinoma as inclusion criteria, 1 is no phase specified (1 open) .
Colorectal Carcinoma +
Malignant Solid Tumor +
Bladder Carcinoma +
Head And Neck Carcinoma +
Ovarian Carcinoma +
Anaplastic Astrocytoma +
Pancreatic Carcinoma +
Breast Carcinoma +
Diffuse Intrinsic Pontine Glioma +
HGF is an inclusion criterion in 1 clinical trial for diffuse intrinsic pontine glioma, of which 1 is open and 0 are closed. Of the trial that contains HGF status and diffuse intrinsic pontine glioma as inclusion criteria, 1 is phase 1 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.